Semnur Pharmaceuticals
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
960 San Antonio Rd, Palo Alto, Californi...Phone Number
(650) 422-7515Website
www.semnurpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Semnur Pharmaceuticals
Semnur Pharmaceuticals, Inc. is a clinical-stage specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of chronic pain, particularly conditions associated with the spine and nervous system. Headquartered in Palo Alto, California, the company concentrates its research and development efforts on creating non-opioid pain management solutions designed to address significant unmet medical needs while reducing reliance on traditional opioid-based treatments. Its scientific strategy centers on developing advanced formulations and targeted therapies that improve safety, efficacy, and patient outcomes for individuals suffering from debilitating pain conditions.Explore more
Semnur Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Semnur Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Semnur Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Semnur Pharmaceuticals
Funding: Get notified immidiatlly once Semnur Pharmaceuticals has new funding data
Click to see if Semnur Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Semnur Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Semnur Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Semnur Pharmaceuticals launches new products
Check out if Semnur Pharmaceuticals is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Semnur Pharmaceuticals
Compare insights from companies similar to Semnur Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Semnur Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Semnur Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Semnur Pharmaceuticals.
Semnur Pharmaceuticals financials insights
Gather financial insights about Semnur Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$6M
Semnur Pharmaceuticals Tech Stack
A closer look at the technologies used by Semnur Pharmaceuticals
Semnur Pharmaceuticals News & Media
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Dream Bowl I Meme Coin tokens (“Dream Bowl Tokens”) commence trading on the Biconomy Exchange on July 6, 2026.Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced the signing of a binding term sheet with iHolding Group LLP ("iHolding"), a private investment group headquartered in Almaty, Republic ofScilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026
PALO ALTO, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced Dream Bowl I Meme Coin tokens (“Dream Bowl Tokens”) to list on Biconomy Exchange as early as June 23, 2026.Scilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
PALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today confirmed the previously announced payment date of June 15, 2026 (the “Payment Date”) for the dividend of Semnur Pharmaceuticals, Inc. (“Semnur”) (O
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Semnur Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Semnur Pharmaceuticals, Inc. is a clinical-stage specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of chronic pain, particularly conditions associated with the spine and nervous system. Headquartered in Palo Alto, California, the company concentrates its research and devel... Read More
